CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $1.56M, lower than 95% of all stocks globally
- PositionOperating margin is -10741.5%, lower than 95% of its Biotechnology peers (median -24.1%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.67BUSDvs all stocks (USD)
Revenue (TTM)
1.56MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.44xvs all stocks
52-Week Change
227.94%vs all stocks
Market Capitalization
1.67BUSDvs all stocks (USD)
Enterprise Value
1.58BUSDvs all stocks (USD)
Forward P/E
-15.32xvs Biotechnology peers
Price to Book (MRQ)
7.21xvs Biotechnology peers
Enterprise to Revenue
1.01Kxvs Biotechnology peers
Enterprise to EBITDA
-13.21xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-34.09%vs Biotechnology peers
Return on Equity (TTM)
-57.72%vs Biotechnology peers
Revenue (TTM)
1.56MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0100USDUpdated Sep 26, 2026Quarterly Revenue Growth
-46.40%vs Biotechnology peers
Gross Profit (TTM)
-84.23MUSDvs all stocks (USD)
EBITDA (TTM)
-119.51MUSDvs all stocks (USD)
Net Income (TTM)
-121.08MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-46.37%vs Biotechnology peers
Operating Cash Flow (TTM)
-108.08MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-50.59MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 26, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
2.80MUSDFY2025 · Dec 31, 2025Operating Income
-125.42MUSDvs all stocks (USD)
Pre-tax Income
-115.11MUSDFY2025 · Dec 31, 2025Income Tax Expense
69.00KUSDFY2025 · Dec 31, 2025Net Income
-115.18MUSDFY2025 · Dec 31, 2025EBIT
-114.91MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-108.26MUSDFY2025 · Dec 31, 2025Research & Development
81.42MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
35.06MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
209.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.8400USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.8400USDFY2025 · Dec 31, 2025Basic Shares Outstanding
136.78MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
136.78MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-115.18MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-91.05MUSDFY2025 · Dec 31, 2025Free Cash Flow
-91.26MUSDDerived from operating cash flow minus capital expenditure. This filing charges 11.74M of depreciation against 205K of capital expenditure, and its own free-cash-flow line reads -94.03M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
21.08MUSDFY2025 · Dec 31, 2025Interest Paid
178.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-115.18MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
11.74MUSDFY2025 · Dec 31, 2025Stock-based Compensation
18.32MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-5.68MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
0.00USDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-247.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
205.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-119.87MUSDFY2025 · Dec 31, 2025Sale of Investments
69.50MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-50.16MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-3.20MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
102.64MUSDFY2025 · Dec 31, 2025Shares Outstanding
171.56MSharesUpdated Sep 26, 2026Float Shares
163.79MSharesUpdated Sep 26, 2026Shares Short
36.79MSharesUpdated Sep 26, 2026Short Ratio
13.57daysvs all stocks
Short % of Shares Outstanding
26.08%vs all stocks
% Held by Insiders
11.84%vs all stocks
% Held by Institutions
87.24%vs all stocks
Total Cash (MRQ)
201.14MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.17USDUpdated Sep 26, 2026Total Debt (MRQ)
3.83MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0156xvs Biotechnology peers
Current Ratio (MRQ)
10.63xvs Biotechnology peers
Book Value per Share (MRQ)
1.44USDUpdated Sep 26, 2026Total Assets
216.30MUSDvs all stocks (USD)
Total Current Assets
149.57MUSDFY2025 · Dec 31, 2025Total Liabilities
26.85MUSDFY2025 · Dec 31, 2025Total Non-current Assets
66.72MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
4.08MUSDFY2025 · Dec 31, 2025Total Current Liabilities
22.77MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
20.02MUSDFY2025 · Dec 31, 2025Other Short-term Investments
124.27MUSDFY2025 · Dec 31, 2025Accounts Payable
2.76MUSDFY2025 · Dec 31, 2025Short-term Debt
2.68MUSDFY2025 · Dec 31, 2025Deferred Revenue
739.00KUSDFY2025 · Dec 31, 2025Long-term Debt
2.62MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.02MUSDFY2025 · Dec 31, 2025Common Stock (Book)
15.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-624.78MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
189.45MUSDvs all stocks (USD)
52-Week Low
2.24USDUpdated Sep 26, 202652-Week High
12.05USDUpdated Sep 26, 202652-Week Change
227.94%vs all stocks
Beta
2.44xvs all stocks
50-Day MA
8.73USDUpdated Sep 26, 2026200-Day MA
5.63USDUpdated Sep 26, 2026Avg 10-Day Volume
4.73MSharesUpdated Sep 26, 2026Avg 30-Day Volume
3.45MSharesUpdated Sep 26, 2026Diluted EPS (TTM)
-0.7900USDUpdated Sep 26, 2026Other Income / Expense
10.51MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -10741.5%, lower than 95% of its Biotechnology peers (median -24.1%)Significant
Operating margin: -107.415Industry median: -0.24Industry P5: -33.54Peers compared: 193
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.60
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $1.56M, lower than 95% of all stocks globallySignificant
Revenue (USD): 1,561,000Global P5: 33,357,653.812
Market cap is $1.67B, above the global median of $1.18BNotable
Market cap (USD): 1,671,520,457Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Hugel Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Shyndec Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Conba Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nolato AB
Tier 1ProductionApproval-Gated PipelineRule
Tibet Cheezheng Tibetan Medicine Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Olix Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Eton Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hualan Biological Engineering Inc.
Tier 1ProductionApproval-Gated PipelineRule
Marksans Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Pharmablock Sciences Nanjing Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Iovance Biotherapeutics, Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Twist Bioscience Corporation
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
AbCellera Biologics Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC